Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

NCT06185400 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT06185400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06185400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2024
Completion date
December 1, 2026
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

disitamab vedotin, erbb2 gene duplication, erbb2 mutation-related tumors, non small cell lung cancer